Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer

Inclusion Criteria: * Histologically confirmed adenocarcinoma that failed standard curative options and for which no standard palliative options are required within the next 8weeks * Advanced or metastatic disease * Recurrent or unresectable disease * Microscopic metastatic disease confirmed by surgical exploration allowed * CEA expression by immunohistochemistry * Circulating CEA greater than 5 ng/mL * HLA phenotyping required * HLA phenotyping must be repeated for patients who have undergone allogeneic bone marrow transplantation * No clinically symptomatic brain metastases * Patients with brain metastases who have completed palliative radiotherapy and have discontinued steroids are eligible * Hormone receptor status: * Not specified * Male or female * Performance status - ECOG 0-1 * WBC at least 3,000/mm\^3 * Platelet count at least 100,000/mm\^3 * Bilirubin less than 1.5 times upper limit of normal (ULN) * AST and ALT less than 3 times ULN * PT and PTT less than 1.5 times ULN (unless therapeutically anticoagulated) * Creatinine less than 1.5 mg/dL * Creatinine clearance greater than 60 mL/min * Proteinuria or hematuria less than +2 on urinalysis\* * Urine protein less than 1,000 mg/24-hour collection, if proteinuria greater than +1 * No frequent vomiting or severe anorexia * No more than 10% weight loss within the past 3 months * No inflammatory bowel disease, Crohn's disease, ulcerative colitis, or active diverticulitis * No uncontrolled seizure disorder…